Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.